BR112015003393A2 - pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n - Google Patents

pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n

Info

Publication number
BR112015003393A2
BR112015003393A2 BR112015003393A BR112015003393A BR112015003393A2 BR 112015003393 A2 BR112015003393 A2 BR 112015003393A2 BR 112015003393 A BR112015003393 A BR 112015003393A BR 112015003393 A BR112015003393 A BR 112015003393A BR 112015003393 A2 BR112015003393 A2 BR 112015003393A2
Authority
BR
Brazil
Prior art keywords
calcium channel
channel blockers
type calcium
compounds
formula
Prior art date
Application number
BR112015003393A
Other languages
English (en)
Inventor
Flores Christopher
L Wal Mark
Subasinghe Nalin
Sui Zhihua
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49034268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015003393(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112015003393A2 publication Critical patent/BR112015003393A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

abstract disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. such compounds are represented by formula i as follows: formula (i) wherein r1, r2 , ring a, and g are defined herein. tradução do resumo resumo patente de invenção "pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n" a presente invenção refere-se ao compostos, às composições e aos métodos para o tratamento de várias doenças, síndromes, condições e distúrbios, incluindo dor. tais compostos são representados pela fórmula (i) a seguir, fórmula (i) na qual r1, r2, anel a, e g são aqui definidos.
BR112015003393A 2012-08-16 2013-08-16 pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n BR112015003393A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683774P 2012-08-16 2012-08-16
PCT/US2013/055263 WO2014028800A1 (en) 2012-08-16 2013-08-16 Substituted pyrazoles as n-type calcium channel blockers

Publications (1)

Publication Number Publication Date
BR112015003393A2 true BR112015003393A2 (pt) 2017-07-04

Family

ID=49034268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015003393A BR112015003393A2 (pt) 2012-08-16 2013-08-16 pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n

Country Status (18)

Country Link
US (1) US9434693B2 (pt)
EP (1) EP2885278B1 (pt)
JP (1) JP6262732B2 (pt)
KR (1) KR20150042269A (pt)
CN (1) CN104884438B (pt)
AU (1) AU2013302468B2 (pt)
BR (1) BR112015003393A2 (pt)
CA (1) CA2882038A1 (pt)
CL (1) CL2015000360A1 (pt)
CR (1) CR20150067A (pt)
EA (1) EA201590381A1 (pt)
IL (1) IL237190A0 (pt)
IN (1) IN2015DN01238A (pt)
MX (1) MX2015002036A (pt)
PE (1) PE20151138A1 (pt)
PH (1) PH12015500316A1 (pt)
SG (1) SG11201501130PA (pt)
WO (1) WO2014028800A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108484496B (zh) 2012-08-21 2022-03-22 詹森药业有限公司 阿立哌唑半抗原及其在免疫测定中的应用
US9751953B2 (en) 2012-08-21 2017-09-05 Janssen Pharmaceutica Nv Antibodies to risperidone haptens and use thereof
EP3333195B1 (en) 2012-08-21 2020-08-05 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
EP2888287A4 (en) 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
US9611332B2 (en) 2012-08-21 2017-04-04 Janssen Pharmaceutica Nv Antibodies to aripiprazole haptens and use thereof
CN110054693A (zh) 2012-08-21 2019-07-26 詹森药业有限公司 喹硫平半抗原的抗体及其用途
ES2733963T3 (es) 2012-08-21 2019-12-03 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de olanzapina y uso de los mismos
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
US9465041B2 (en) 2012-08-21 2016-10-11 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
MA44056A (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica Nv Anticorps anti-rispéridone et leur utilisation
US20200002283A1 (en) * 2016-06-29 2020-01-02 Esteve Pharmaceuticals, S.A. Pyrazole derivatives having activity against pain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
IT1287174B1 (it) 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2004060367A1 (en) * 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
KR20140015122A (ko) 2003-10-01 2014-02-06 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
FR2864958B1 (fr) 2004-01-12 2006-02-24 Sanofi Synthelabo Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
WO2009000085A1 (en) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Quinoline and quinazoline derivatives useful as modulators of gated ion channels
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2331522B1 (en) 2008-08-01 2013-09-18 Purdue Pharma LP Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
KR101052065B1 (ko) * 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
US8853418B2 (en) 2012-08-16 2014-10-07 Janssen Pharmaceutica Nv Cyclopentylpyrazoles as N-type calcium channel blockers
SG11201501133WA (en) 2012-08-16 2015-04-29 Janssen Pharmaceutica Nv Pyrrolopyrazoles as n-type calcium channel blockers
MX2015002038A (es) 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.

Also Published As

Publication number Publication date
EP2885278B1 (en) 2016-08-03
EP2885278A1 (en) 2015-06-24
US9434693B2 (en) 2016-09-06
JP6262732B2 (ja) 2018-01-17
EA201590381A1 (ru) 2015-07-30
US20140162997A1 (en) 2014-06-12
SG11201501130PA (en) 2015-04-29
AU2013302468B2 (en) 2017-08-24
PE20151138A1 (es) 2015-08-07
CN104884438A (zh) 2015-09-02
KR20150042269A (ko) 2015-04-20
MX2015002036A (es) 2016-01-22
CN104884438B (zh) 2017-07-28
CA2882038A1 (en) 2014-02-20
PH12015500316A1 (en) 2015-03-30
CR20150067A (es) 2015-04-30
JP2015524850A (ja) 2015-08-27
IN2015DN01238A (pt) 2015-06-26
CL2015000360A1 (es) 2015-04-24
IL237190A0 (en) 2015-04-30
WO2014028800A1 (en) 2014-02-20
AU2013302468A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
BR112015003393A2 (pt) pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
BR112015003359A2 (pt) pirrolopirazóis como bloqueadores de canal de cálcio de tipo-n
BR112012010253A8 (pt) compostos de pirimidina como moduladores do receptor delta opioide
BR112013005141A2 (pt) diazetidinil diamida como inibidores de monoacilglicerol lipase
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
BR112014013526A2 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
GT201000015A (es) Sulfonamidas como moduladores de trpms
EA201290644A1 (ru) Блокаторы натриевых потенциал-зависимых каналов
BR112015003395A2 (pt) pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
DOP2015000009A (es) Antagonistas del receptor de 5-ht3
BR112013007287A2 (pt) amidas oxopiperazina-azetidina e amidas oxodiazepina-azetina como inibidores de monoacilglicerol lipase
MX2017008431A (es) Compuestos ciclicos sustituidos con un sistema de anillos condensado.
PH12014502752A1 (en) Novel cyclic depsipeptide derivative and pest control agent compromising same
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
IN2012DN03846A (pt)
MX2012002299A (es) Uso de cetoenoles ciclicos contra bacterias fitopatogenas.
BR112015003328A2 (pt) ciclopentilpirazóis como bloqueadores de canal de cálcio de tipo-n
MX2016002043A (es) Imidazoles sustituidos como bloqueadores de canales de calcio tipo n.
EA201591449A1 (ru) Способы получения противораковых композиций
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.
CY1115324T1 (el) Αζετιδινυλ διαμιδια ως αναστολεις λιπασης μονοακυλγλυκερινης
EA201691191A1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона
IN2013MU01354A (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]